Investor Presentaiton

KEY HIGHLIGHTS Diversified enterprise focused in pharmaceutical sector with presence across geographies - India, US and ROW Strong brand position in domestic pharma segments • Well established player in oncology with brands catering to diseases including breast, bone, lung and ovarian cancer Expanding reach to wider pool of doctors through NATCO REACH • Focused on complex generics for the US Markets with niche Para IV and Para III filings • Established front-end presence through Dash acquisition Two R&D centers with around 465 employees (1) Targeting growth in Crop Health Sciences business with state-of-the-art manufacturing facilities for both technical and formulation Total revenues (2) of ₹28,117 million for the financial year ended 31st March 2023 Listed on BSE and NSE with a market capitalisation (3) of USD 1.89 billion Incorporated in 1981 and headquartered in Hyderabad with around 4,900 employees across all locations (1). (1) As of March 31, 2023 (2) Represents consolidated revenue (3) Market capitalization as of Sept 30, 2023 using INR / USD exchange rate of 83.1073 NATCO 3

View entire presentation